Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc.

Bio-Rad to Report Second-Quarter 2020 Financial Results, Thursday, July 30, 2020

Bio-Rad (BIO) rides on the FDA's emergency use authorization EUA for the Droplet Digital PCR COVID-19 test kit.

Bio-Rad (BIO) Banks on Coronavirus PCR Tests Amid Cost Woes

AmerisourceBergen

United Therapeutics

As the first half of 2020 comes to a close, investors are cautiously looking toward the remainder of the year as uncertainty surrounding the full impact the coronavirus will have on the economy continues to remain a concern.

3 Health Care Companies That Beat the Market in the 1st Half of the Year

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues is the result of robust demand due to coronavirus testing and related research.

Bio-Rad Rides on PCR Test Kits for Coronavirus Amid Cost Woe

Forma Therapeutics Holdings

IMARA

Keros Therapeutics

Vaxcyte

Avidity Biosciences

Repare Therapeutics

SPDR S&P Biotech ETF

Zentalis Pharmaceuticals

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Biotech IPOs are booming -- but it's not all about Covid-19

The uptick in Bio-Rad's (BIO) core PCR and Droplet Digital PCR product revenues results from robust demand for coronavirus testing and related research.

Bio-Rad Rides on New Coronavirus Tests Amid Cost Concerns

Abbott Labs

PerkinElmer

Independent analysis shows some of the post-exposure tests work fairly well.

FDA Evaluates 5 More COVID-19 Antibody Tests

QuidelOrtho Corp

Veeva Systems

Vertex Pharmaceuticals

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why Coronavirus Test Firms Are Among 4 Key Health Care Stocks

Bio-Rad: A Very Interesting Short-Term Investment Thanks To Gains On Sartorius Holding

Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.

Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2020 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 36.43% and 4.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q1 Earnings and Revenues Surpass Estimates

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bio-Rad Laboratories (BIO) Q1 Earnings Expected to Decline

To get ready for earnings season, focus on stocks in or near a potential buy range ahead of their next quarterly report. One company that meets that criteria is Bio.

Bio Rad Labs At Top End Of Buy Range With Earnings Due

Medical stocks cruised higher Thursday led by breakouts from high-ranking players Abbott Laboratories and Bio-Rad Laboratories. The pandemic gives medical stock a chance to shine.

Coronavirus Limelight Sends These Bullish Medical Stocks Into Breakouts

Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.

Bio-Rad Rides on International Expansion Amid Cost Concerns

Bio-Rad (BIO) launches a blood-based immunoassay kit to better detect antibodies in response to SARS-CoV-2 infection.

Bio-Rad Launches Serology Test to Detect Coronavirus Antibody

Global Cord Blood

Fonar

As investors continue grappling with coronavirus fears, three medical companies with high financial strength and trading below Peter Lynch’s valuation line of 15 times earnings are Bio-Rad Industries Inc.

3 Medical Companies With the Strength to Weather Coronavirus Fears

Bio-Rad (BIO) inks partnership deal with Biodesix to receive a EUA for a ddPCR test.

Bio-Rad, Biodesix Partner to Get EUA for Coronavirus Test

Bio-Rad's (BIO) ddPCR System shows better sensitivity and precision in the detection of SARS-CoV-2, unlike existing qPCR tests.

Bio-Rad's ddPCR System Detects Coronavirus More Accurately

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

Why Is Bio-Rad (BIO) Down 8.3% Since Last Earnings Report?

With the launch of Bio-Rad's (BIO) SARS CoV-2 Standard, it aims to help laboratories validate coronavirus testing and accelerate the access to testing.

Bio-Rad Launches SARS CoV-2 Standard for Coronavirus Testing

Exact Sciences

There's a strong case to be made for both companies, but which one is a better investment?

Better Buy: Exact Sciences vs. Bio-Rad Laboratories

Bio-Rad's (BIO) fourth-quarter 2019 results reflect strong segmental performances.

Bio-Rad (BIO) Q4 Earnings & Revenues Fall Short of Estimates

Bio-Rad's Q4 revenue and earnings were disappointing, but its 2020 outlook looked good.

News for Bio-Rad Laboratories Stock (BIO)